Weight Gain and Comorbidities Associated with Oral Second-Generation Antipsychotics: Analysis of Patients with Bipolar I Disorder or Schizophrenia

Clinically significant weight gain (CSWG) is associated with increased morbidity and mortality. This study describes CSWG and comorbidities observed in patients with bipolar I disorder (BD-I) and schizophrenia (SZ) after initiating select second-generation antipsychotics (SGAs). Percent change in we...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CNS spectrums 2022-04, Vol.27 (2), p.240-240
Hauptverfasser:	Meyer, Jonathan M., Bessonova, Leona, Friedler, Haley S., Mortimer, Kathleen M., Cheng, Harry, Brecht, Thomas, O’Sullivan, Amy K., Cummings, Hannah, McDonnell, David, Doane, Michael J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abstracts Antipsychotic Agents - adverse effects Antipsychotics Bipolar disorder Bipolar Disorder - chemically induced Bipolar Disorder - drug therapy Bipolar Disorder - epidemiology Cardiovascular disease Clinical significance Comorbidity Diabetes Mellitus, Type 2 Humans Obesity Obesity - chemically induced Obesity - epidemiology Olanzapine - therapeutic use Overweight Overweight - chemically induced Overweight - epidemiology Psychotropic drugs Schizophrenia Schizophrenia - drug therapy Schizophrenia - epidemiology Thinness - chemically induced Weight Gain
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!